Security
Xilio Therapeutics, Inc. Common Stock · XLO
XLONASDAQCommon stockCurrentCIK 1840233Updated Nov 17, 2026
XLO price & chart
Loading TradingView…
NASDAQ:XLO on TradingView ↗About the company
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our clinically-validated masking technology and capabilities, Xilio is developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
In the news
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Seeking Alpha
Xilio Therapeutics GAAP EPS of -$0.30 beats by $0.64, revenue of $9.98M beats by $5.06M ↗
Xilio Therapeutics GAAP EPS of -$0.33, revenue of $18.7M ↗
Xilio Therapeutics reports Q1 results ↗
SEC disclosures
Xilio Therapeutics, Inc. files 8-K: Material Event ↗
Recent filings
SCHEDULE 13G - filed by Logos Global Management LP regarding Xilio Therapeutics, Inc.
SCHEDULE 13G - filed by Adage Capital Management, L.P. regarding Xilio Therapeutics, Inc.
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
SCHEDULE 13G/A - filed by STEMPOINT CAPITAL LP regarding Xilio Therapeutics, Inc.
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 133,694,000Source | 74,658,000Source | 154,254,000Source | 133,813,000Source | 89,873,000Source | 163,487,000Source | 103,716,000Source | 82,609,000Source | 154,685,000Source | 71,075,000Source | 60,926,000Source | 139,165,000Source |
| Property, Plant and Equipment, NetUSD | 3,679,000Source | 4,845,000Source | 3,359,000Source | 4,018,000Source | 5,137,000Source | 3,680,000Source | 4,289,000Source | 5,542,000Source | 3,892,000Source | 4,472,000Source | 5,942,000Source | 7,255,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 103,764,000Source | 61,259,000Source | 136,040,000Source | 121,551,000Source | 74,949,000Source | 150,333,000Source | 89,073,000Source | 33,980,000Source | 137,531,000Source | 55,291,000Source | 44,704,000Source | 120,385,000Source |
| Assets, CurrentUSD | 124,089,000Source | 63,309,000Source | 145,468,000Source | 123,716,000Source | 78,008,000Source | 154,207,000Source | 93,200,000Source | 69,185,000Source | 145,027,000Source | 60,234,000Source | 48,127,000Source | 124,496,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,825,000Source | 2,050,000Source | 3,428,000Source | 2,165,000Source | 3,059,000Source | 3,874,000Source | 4,127,000Source | 5,205,000Source | 2,496,000Source | 4,943,000Source | 3,423,000Source | 4,111,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,125,000Source | 4,729,000Source | 3,608,000Source | 4,285,000Source | 4,867,000Source | 3,787,000Source | 4,439,000Source | 4,998,000Source | 3,959,000Source | 4,587,000Source | 5,125,000Source | 5,585,000Source |
| Other Assets, NoncurrentUSD | — | — | — | — | 92,000Source | — | — | 121,000Source | — | — | 145,000Source | 267,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 141,789,000Source | 53,684,000Source | 81,990,000Source | 126,744,000Source | 56,457,000Source | 90,942,000Source | 93,016,000Source | 56,844,000Source | 119,412,000Source | 53,477,000Source | 24,099,000Source | 33,518,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 5,000Source | 4,000Source | 1,000Source | 5,000Source | 4,000Source | 1,000Source | 5,000Source | 3,000Source | — | 5,000Source | 3,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 421,049,000Source | 391,630,000Source | 506,954,000Source | 419,926,000Source | 390,052,000Source | 500,862,000Source | 407,713,000Source | 368,477,000Source | 454,062,000Source | 401,346,000Source | 362,336,000Source | 354,752,000Source |
| Retained Earnings (Accumulated Deficit)USD | -429,149,000Source | -370,660,000Source | -434,691,000Source | -412,862,000Source | -356,640,000Source | -428,318,000Source | -397,018,000Source | -342,715,000Source | -418,789,000Source | -383,753,000Source | -325,512,000Source | -249,108,000Source |
| Stockholders' Equity Attributable to ParentUSD | -8,095,000Source | 20,974,000Source | 72,264,000Source | 7,069,000Source | 33,416,000Source | 72,545,000Source | 10,700,000Source | 25,765,000Source | 35,273,000Source | 17,598,000Source | 36,827,000Source | 105,647,000Source |
| Liabilities and EquityUSD | 133,694,000Source | 74,658,000Source | 154,254,000Source | 133,813,000Source | 89,873,000Source | 163,487,000Source | 103,716,000Source | 82,609,000Source | 154,685,000Source | 71,075,000Source | 60,926,000Source | 139,165,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 56,401,000Source | 38,022,000Source | 34,198,000Source | 53,260,000Source | 38,641,000Source | 42,960,000Source | 47,637,000Source | 31,582,000Source | 56,273,000Source | 27,261,000Source | 15,957,000Source | 21,119,000Source |
| Operating Lease, Liability, CurrentUSD | 1,303,000Source | 1,152,000Source | 1,426,000Source | 1,264,000Source | 1,116,000Source | 1,384,000Source | 1,226,000Source | 1,081,000Source | 1,343,000Source | 1,188,000Source | 1,047,000Source | 918,000Source |
| Accounts Payable, CurrentUSD | 2,300,000Source | 972,000Source | 2,315,000Source | 4,097,000Source | 1,264,000Source | 1,064,000Source | 2,275,000Source | 746,000Source | 3,168,000Source | 2,574,000Source | 1,050,000Source | 3,125,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,960,000Source | 7,263,000Source | 4,877,000Source | 6,302,000Source | 7,566,000Source | 5,254,000Source | 6,638,000Source | 7,863,000Source | 5,611,000Source | 6,954,000Source | 8,142,000Source | 9,189,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 45,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 8,952,000Source | 9,793,000Source | 7,854,000Source | 5,621,000Source | 9,737,000Source | 8,970,000Source | 3,883,000Source | 8,002,000Source | 11,739,000Source | 9,981,000Source | 10,497,000Source | 10,327,000Source |
| Deferred Revenue, CurrentUSD | 43,846,000Source | 26,105,000Source | 22,603,000Source | 42,278,000Source | 26,517,000Source | 31,542,000Source | 40,253,000Source | 21,725,000Source | 40,023,000Source | 13,518,000Source | — | — |
| Deferred Revenue, NoncurrentUSD | 25,498,000Source | 8,399,000Source | 12,715,000Source | 28,632,000Source | 10,250,000Source | 16,468,000Source | 38,741,000Source | 17,399,000Source | 20,635,000Source | 19,262,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -9,529,000Source | -13,265,000Source | -35,036,000Source | -58,241,000Source | -76,404,000Source | -88,222,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 344,000Source | 497,000Source | 1,541,000Source | 1,644,000Source | 1,900,000Source | 1,847,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,211,000Source | 1,535,000Source | 6,939,000Source | 6,434,000Source | 7,382,000Source | 8,424,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -5,000,000Source | 0Source | 5,000,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,680,000Source | -590,000Source | 152,000Source | 1,526,000Source | -2,063,000Source | 485,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -22,343,000Source | 28,978,000Source | -4,992,000Source | -18,378,000Source | -68,620,000Source | -75,723,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -556,000Source | -22,000Source | -518,000Source | -36,000Source | -486,000Source | -1,867,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 556,000Source | 22,000Source | 518,000Source | 36,000Source | 486,000Source | 1,867,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 35,707,000Source | 4,832,000Source | 87,775,000Source | 29,196,000Source | -6,550,000Source | -69,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 12,808,000Source | 33,788,000Source | 82,265,000Source | 10,782,000Source | -75,656,000Source | -77,659,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 105,565,000Source | 63,034,000Source | 137,859,000Source | 123,345,000Source | 152,146,000Source | 90,861,000Source | 139,338,000Source | 57,073,000Source | 46,291,000Source | 121,947,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 62,000Source | 573,000Source | 555,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,123,000Source | 1,574,000Source | 1,598,000Source | 1,351,000Source | 2,211,000Source | 1,535,000Source | 6,939,000Source | 6,434,000Source | 7,382,000Source | 8,424,000Source |
| DepreciationUSD | — | — | 300,000Source | 400,000Source | 300,000Source | 400,000Source | 300,000Source | 500,000Source | 1,500,000Source | 1,600,000Source | 1,800,000Source | 1,700,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | -3,000Source | -3,000Source | -1,000Source |
| General and Administrative ExpenseUSD | — | — | 6,674,000Source | 6,307,000Source | 7,624,000Source | 7,120,000Source | 6,928,000Source | 8,515,000Source | 29,709,000Source | 24,778,000Source | 26,997,000Source | 29,948,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,287,000Source | -14,020,000Source | -6,373,000Source | -15,844,000Source | -9,529,000Source | -13,265,000Source | -35,036,000Source | -58,241,000Source | -76,404,000Source | -88,222,000Source |
| Nonoperating Income (Expense)USD | — | — | -14,358,000Source | 742,000Source | -2,882,000Source | -1,478,000Source | 4,583,000Source | 586,000Source | 6,946,000Source | 2,341,000Source | 2,729,000Source | 927,000Source |
| Operating ExpensesUSD | — | — | 20,995,000Source | 17,025,000Source | 22,183,000Source | 22,450,000Source | 26,760,000Source | 16,781,000Source | 85,748,000Source | 66,926,000Source | 79,133,000Source | 89,149,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,022,000Source | 742,000Source | 1,058,000Source | -1,428,000Source | 1,283,000Source | 586,000Source | 1,101,000Source | 2,341,000Source | 2,729,000Source | 927,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,000Source | 5,000Source | 10,000Source | 5,000Source | 8,000Source | 16,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 19,066,000Source | 2,263,000Source | 18,692,000Source | 8,084,000Source | 12,648,000Source | 2,930,000Source | 43,766,000Source | 6,344,000Source | — | — |
| Operating Income (Loss)USD | — | — | -1,929,000Source | -14,762,000Source | -3,491,000Source | -14,366,000Source | -14,112,000Source | -13,851,000Source | -41,982,000Source | -60,582,000Source | -79,133,000Source | -89,149,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,022,000Source | 742,000Source | 1,058,000Source | -1,428,000Source | 1,283,000Source | 586,000Source | 1,101,000Source | 2,341,000Source | 2,729,000Source | 927,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -35,036,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,287,000Source | -14,020,000Source | -6,373,000Source | -15,844,000Source | -9,529,000Source | -13,265,000Source | -35,036,000Source | -58,241,000Source | -76,404,000Source | -88,222,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.11Source | -0.22Source | -0.33Source | -2.3Source | -0.58Source | -2.49Source | -4.19Source | -1.09Source | -2.78Source | -3.22Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.11Source | -0.22Source | -0.33Source | -2.3Source | -0.58Source | -2.49Source | -4.19Source | -1.09Source | -2.78Source | -3.22Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 144,106,869Source | 63,465,063Source | 19,404,688Source | 6,889,119Source | 16,347,538Source | 5,335,740Source | 8,359,109Source | 53,511,424Source | 27,496,107Source | 27,392,087Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 6,674,000Source | 6,307,000Source | 7,624,000Source | 7,120,000Source | 6,928,000Source | 8,515,000Source | 29,709,000Source | 24,778,000Source | 26,997,000Source | 29,948,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -35,036,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | -14,358,000Source | 742,000Source | -2,882,000Source | -1,478,000Source | 4,583,000Source | 586,000Source | 6,946,000Source | 2,341,000Source | 2,729,000Source | 927,000Source |
| Operating ExpensesUSD | — | — | 20,995,000Source | 17,025,000Source | 22,183,000Source | 22,450,000Source | 26,760,000Source | 16,781,000Source | 85,748,000Source | 66,926,000Source | 79,133,000Source | 89,149,000Source |
| Research and Development ExpenseUSD | — | — | 14,321,000Source | 10,759,000Source | 14,559,000Source | 15,330,000Source | 19,832,000Source | 8,266,000Source | 56,039,000Source | 41,211,000Source | 52,136,000Source | 59,201,000Source |
Offerings
Registration 333-295785
Filing attachments
p15116163_ex99-1.htm · SCHEDULE 13G · 2026-11-12
EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗xlo-ex99_1.htm · 8-K · 2026-11-10
Exhibit 99.1 Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates Dosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan to report initial Phase 1 data in the fourth quarter of 2027 Advancing XTX602, a dual-masked CLDN18.2-targeting multi-specific TCE with co-stimulation, and XTX701, a masked PSMAxSTEAP1-targeting multi-specific TCE wit…
Read attachment ↗tm2621614d4_ex99-1.htm · SCHEDULE 13G/A · 2026-08-14
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of th…
Read attachment ↗xlo-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 xlo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1; IND applications anticipated in the second half of 2027 Cash runway into the…
Read attachment ↗xlo-ex4_3.htm · S-3/A · 2026-05-27
Exhibit 4.3 XILIO THERAPEUTICS, INC. and Trustee INDENTURE Dated as of _______________ SENIOR DEBT SECURITIESCROSS-REFERENCE TABLE1 Section of Trust Indenture Act Section of Indenture of 1939, as amended ──────────────────────────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6…
Read attachment ↗xlo-ex4_4.htm · S-3/A · 2026-05-27
Exhibit 4.4 XILIO THERAPEUTICS, INC. and Trustee INDENTURE Dated as of _______________ SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act Section of of 1939, as amended Indenture ──────────────────────────────────────────────────── 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) …
Read attachment ↗